心肌梗塞市場規模、佔有率和成長分析：按類型、診斷、治療、藥物類別、最終用戶和地區分類－2026-2033年產業預測

2024 年全球心肌梗塞市場價值為 26.7 億美元，預計到 2025 年將成長至 28.2 億美元，到 2033 年將成長至 152.8 億美元，在預測期（2026-2033 年）內複合年成長率為 5.5%。

全球心肌梗塞市場因其全球首要死因的地位而蓬勃發展，該市場整合了藥品、介入性醫療設備和診斷服務，以應對急性冠狀動脈事件。人口老化和生活方式相關風​​險因素導致的心肌梗塞發生率上升，正在加速產品創新，包括新型抗血小板藥物和藥物釋放型支架的問世。數位醫療的進步正在改變市場格局，催生出可擴展的解決方案，透過電子健康記錄和即時監測實現早期檢測。尤其值得關注的是，人工智慧應用，特別是那些能夠分析臨床數據以加速診斷的應用，正日益受到關注。這種轉變正在消除臨床工作流程中的瓶頸，並推動該領域的投資。此外，保險報銷制度的改革正將重點從急性治療轉向長期風險管理，為創新解決方案創造了更廣泛的市場機會。

全球心肌梗塞市場成長要素

人口老化是導致心肌梗塞發病率顯著上升的重要因素，進而造成對急性期護理、藥物治療和發病後復健服務的持續需求。為此，醫療衛生系統正在加強心臟專科治療部門建設，並投資研發先進的治療性醫療設備，這些器械透過提高使用率和持續創新來推動市場發展。此外，老年人對心血管危險因子的認知不斷提高，促進了預防性篩檢工作，從而增加了診斷檢測和早期治療性介入。這為持續的病患監測提供了支持，並進一步推動了市場擴張。

全球心肌梗塞市場的限制因素

由於創新支架和生物製藥等先進療法的高成本，全球心肌梗塞治療市場面臨嚴峻的限制。高昂的價格給醫療系統和病人都帶來了沉重的經濟負擔，導致處方藥清單受到嚴格限制，保險公司也開始實施預先核准流程。這些措施往往導致治療啟動延遲，並限制了新技術市場進入。因此，醫療服務提供者可能會選擇成熟的、成本較低的替代方案，而不是高價值產品，這抑制了整體市場需求。此外，這些新療法的長期成本效益不確定性，這阻礙了保險報銷工作，並限制了它們在不同地區的普及應用。

全球心肌梗塞市場趨勢

在全球心肌梗塞市場，基因組分析技術的進步使得基於個人遺傳風險因素的個人化治療成為可能，從而顯著推動了個人化基因組治療的發展。這種從通用療法轉向精準醫療的轉變不僅能夠改善患者預後，還能最大限度地減少不必要的治療。製藥公司正日益專注於研發包括伴隨診斷在內的產品線，並與生技公司和學術機構合作，共同開發創新解決方案。這種策略性定位使得針對特定療法的產品能夠獲得更高的定價，也反映了全球心肌梗塞治療領域向高度標靶療法發展的持續趨勢。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球心肌梗塞市場規模：依類型分類

• ST段上升型心肌梗塞（STEMI）
• 非ST段上升型心肌梗塞（NSTEMI）

全球心肌梗塞市場規模：依診斷方式分類

• 心電圖（ECG）
• 心臟生物標記檢測
• 冠動脈攝影術
• 心臟超音波圖
• 其他

全球心肌梗塞市場規模：依治療方法分類

• 藥物治療
• 經皮冠狀動脈介入治療（PCI）
• 冠狀動脈繞道手術手術（CABG）
• 其他介入性手術

全球心肌梗塞市場規模：依藥物類別分類

• 抗血小板藥物
• 抗凝血物
• 溶栓劑
• BETA受體阻斷劑
• ACE抑制劑與ARB
• 他汀類藥物
• 其他

全球心肌梗塞市場規模：依最終用戶分類

• 醫院
• 心臟護理中心
• 門診手術中心（ASC）
• 專科診所

全球心肌梗塞市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc
• Johnson & Johnson
• Bayer AG
• Novartis AG
• AstraZeneca plc
• Sanofi Aventis US LLC
• Merck & Co Inc
• Roche Holding AG
• Eli Lilly and Company
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Abbott Laboratories
• Teva Pharmaceutical Industries Ltd
• Daiichi Sankyo Company Limited
• Apotex Inc
• Sandoz International GmbH
• Mylan NV
• Viatris Inc
• Chiesi Farmaceutici SpA
• Sun Pharmaceutical Industries Ltd

結論與建議

Global Myocardial Infarction Market size was valued at USD 2.67 Billion in 2024 and is poised to grow from USD 2.82 Billion in 2025 to USD 15.28 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global myocardial infarction market integrates pharmaceuticals, interventional devices, and diagnostic services to address acute coronary events, driven by its status as a leading cause of global mortality. The rising incidence, attributed to aging populations and lifestyle-related risk factors, has prompted accelerated product innovation, including the introduction of novel antiplatelet agents and drug-eluting stents. Digital health advancements are transforming the landscape, enabling scalable solutions that enhance early detection through electronic health records and real-time monitoring, particularly with AI applications that analyze clinical data for faster diagnostics. This shift is reducing bottlenecks in clinical workflows and fostering investment in the sector. Furthermore, reimbursement reforms are expanding focus from acute care to long-term risk management, creating wider market opportunities for innovative solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Myocardial Infarction market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Myocardial Infarction Market Segments Analysis

Global myocardial infarction market is segmented by type, diagnosis, treatment, drug class, end user and region. Based on type, the market is segmented into ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Based on diagnosis, the market is segmented into Electrocardiogram (ECG), Cardiac Biomarker Tests, Coronary Angiography, Echocardiography and Others. Based on treatment, the market is segmented into Pharmacological Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG) and Other Interventional Procedures. Based on drug class, the market is segmented into Antiplatelet Agents, Anticoagulants, Thrombolytic Agents, Beta-Blockers, ACE Inhibitors & ARBs, Statins and Others. Based on end user, the market is segmented into Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers (ASCs) and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Myocardial Infarction Market

The rise in the aging population contributes significantly to the growing prevalence of myocardial infarction, thereby driving a persistent need for acute care, medication, and rehabilitation services post-event. In response, healthcare systems are enhancing their specialized cardiac units and investing in advanced therapeutic devices, which boosts market development through increased use and continuous innovation. Moreover, heightened awareness of cardiovascular risk factors among older adults promotes preventive screening initiatives, leading to an uptick in diagnostic procedures and early treatment interventions, which in turn support ongoing patient monitoring efforts and further propel market expansion.

Restraints in the Global Myocardial Infarction Market

The global market for myocardial infarction treatments faces notable constraints due to the high costs associated with advanced therapies, such as innovative stents and biologic agents. This premium pricing creates substantial financial strain on both healthcare systems and patients, leading payers to implement strict formulary limitations and necessitate prior authorization processes. These measures often result in delays in treatment initiation and restrict market access for newer technologies. As a result, healthcare providers may choose to use established, lower-cost alternatives instead of high-value products, restraining overall market demand. Furthermore, uncertainties regarding the long-term cost-effectiveness of these novel interventions hinder reimbursement efforts, limiting their adoption in various areas.

Market Trends of the Global Myocardial Infarction Market

The Global Myocardial Infarction market is experiencing a significant shift towards personalized genomic therapies, as advances in genomic profiling allow for tailored treatments based on individual genetic risk factors. This transition from generic interventions to precision medicine not only enhances patient outcomes but also minimizes unnecessary treatments. Pharmaceutical companies are increasingly focusing on developing pipelines that include companion diagnostics, partnering with biotech firms and academic institutions to create innovative solutions. This strategic positioning enables them to command premium pricing for specialized therapies, reflecting a sustainable trend towards highly targeted interventions in the myocardial infarction landscape globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Myocardial Infarction Market Size by Type & CAGR (2026-2033)

• Market Overview
• ST-Elevation Myocardial Infarction (STEMI)
• Non-ST-Elevation Myocardial Infarction (NSTEMI)

Global Myocardial Infarction Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Electrocardiogram (ECG)
• Cardiac Biomarker Tests
• Coronary Angiography
• Echocardiography
• Others

Global Myocardial Infarction Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Pharmacological Therapy
• Percutaneous Coronary Intervention (PCI)
• Coronary Artery Bypass Grafting (CABG)
• Other Interventional Procedures

Global Myocardial Infarction Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antiplatelet Agents
• Anticoagulants
• Thrombolytic Agents
• Beta-Blockers
• ACE Inhibitors & ARBs
• Statins
• Others

Global Myocardial Infarction Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cardiac Care Centers
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics

Global Myocardial Infarction Market Size & CAGR (2026-2033)

• North America (Type, Diagnosis, Treatment, Drug Class, End User)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, Drug Class, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, Drug Class, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, Drug Class, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, Drug Class, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Aventis US LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici SpA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations